Movers and SHAKERS
Ayala Pharmaceuticals (AYLA)
Buying Opportunity With Clinical Trial Milestones Ahead
Ayala Pharmaceuticals Inc clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The company's current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. Its product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma secretase inhibitor, or GSI. It is also developing AL101 for the treatment of T-ALL, an aggressive, rare form of T-cell specific leukemia.
Robert LeBoyer, Vice President, Research Analyst, Life Sciences, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Ayala Is Developing Drugs To Block Activation Of The Notch Pathway. Under normal conditions, the Notch pathway provides signals that regulate cell growth and maintenance. Mutations in the Notch pathway can lead to loss of regulation and proliferation of cancerous cells. Ayala has developed drugs that block gamma secretase, an enzyme that activates the Notch pathway.
AL102 and AL102 Act By Inhibiting An Activation Step In The Notch Pathway. Ayala has developed AL101 and AL102, two drugs that block gamma secretase, an enzyme needed to activate the Notch pathway. This stops the signaling steps that lead to overactivity and proliferation of cancer cells ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.